Abide Therapeutics

Our mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in Nature with validated, but mostly untapped therapeutic potential. Hundreds of serine hydrolases exist in humans and include lipases, amidases, esterases, thioesterases, proteases and peptidases, which all share a base-activated serine nucleophile that cleaves an amide or ester bond. Serine hydrolases play a key role in regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, life cycle of viruses and pathogens. The Abide technology selectively and near-universally targets this enzyme class in their native configuration for functional profiling and inhibitor discovery and optimization.
Type
Private
HQ
San Diego, US
Founded
2011
Employees
36 (est)-2%
Abide Therapeutics was founded in 2011 and is headquartered in San Diego, US

Key People at Abide Therapeutics

Todd Jones

Todd Jones

VP
Alan Ezekowitz

Alan Ezekowitz

President, Co-Founder, CEO
Stan Blackburn

Stan Blackburn

CFO

Abide Therapeutics Locations

San Diego, US
Princeton, US

Abide Therapeutics Metrics

Abide Therapeutics Summary

Founding Date

2011

Total Funding

$2.25 M

Latest funding size

$2.25 M

Time since last funding

about 5 years
Abide Therapeutics's latest funding round of $2.25 M was in November 2011. In total, Abide Therapeutics has raised $2.25 M.
40% of current employees of Abide Therapeutics are female and 60% are male.

Abide Therapeutics News

Abide Therapeutics Company Life

You may also be interested in